These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17120594)

  • 41. [Prevalence of Raynaud's phenomenon in individuals not using vibrating tools].
    Iwata H; Makimo S; Miyashita K
    Sangyo Igaku; 1987 Nov; 29(6):500-3. PubMed ID: 3448316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon.
    Rodriguez VE; Gonzalez-Pares EN; Rivera C
    P R Health Sci J; 2006 Dec; 25(4):307-13. PubMed ID: 17550096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus.
    Grönhagen CM; Gunnarsson I; Svenungsson E; Nyberg F
    Lupus; 2010 Sep; 19(10):1187-94. PubMed ID: 20501526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulmonary hypertension in systemic lupus erythematosus: a report of four cases.
    Hodson P; Klemp P; Meyers OL
    Clin Exp Rheumatol; 1983; 1(3):241-5. PubMed ID: 6681141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.
    Doria A; Ghirardello A; Boscaro M; Viero ML; Vaccaro E; Patrassi GM; Gambari PF
    Rheumatol Int; 1995; 14(5):207-11. PubMed ID: 7724997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival.
    Min HK; Lee JH; Jung SM; Lee J; Kang KY; Kwok SK; Ju JH; Park KS; Park SH
    Korean J Intern Med; 2015 Mar; 30(2):232-41. PubMed ID: 25750566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibodies to hn-RNP protein A1 in systemic lupus erythematosus: clinical association with Raynaud's phenomenon and esophageal dysmotility.
    Montecucco C; Caporali R; Cobianchi F; Negri C; Astaldi-Ricotti GC
    Clin Exp Rheumatol; 1992; 10(3):223-7. PubMed ID: 1582066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic algorithm for Raynaud's phenomenon and vascular skin lesions in systemic lupus erythematosus.
    Richter JG; Sander O; Schneider M; Klein-Weigel P
    Lupus; 2010 Aug; 19(9):1087-95. PubMed ID: 20693202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina.
    Nakamura Y; Shinozaki N; Hirasawa M; Kato R; Shiraishi K; Kida H; Usuda K; Ishikawa T
    Jpn Circ J; 2000 Apr; 64(4):239-42. PubMed ID: 10783043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Critical peripheral ischemia precipitated by severe episode of Raynaud's phenomenon in a patient with aPL-positive systemic lupus erythematosus, upon high titer anti-RNP seroconversion.
    Levy O; Maslakov I; Vosco S; Markov A; Amit-Vazina M; Tishler M
    Lupus; 2015 Mar; 24(3):327-30. PubMed ID: 25467391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dysimmune rheumatism in Raynaud's syndrome (inflammatory rheumatism, Raynaud's syndrome, speckled antinuclear factors and anti-ribonucleoprotein antibody): a new syndrome?].
    Appelboom T; Kahn MF; Peltier AP; de SEZE S
    Ann Med Interne (Paris); 1974 Nov; 125(11):841-8. PubMed ID: 4218716
    [No Abstract]   [Full Text] [Related]  

  • 53. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset.
    Costallat LT; Coimbra AM
    Clin Exp Rheumatol; 1994; 12(6):603-7. PubMed ID: 7895393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of clinical and laboratory parameters for systemic lupus erythematosus activity in Israelis versus Europeans.
    Levy Y; George J; Hojnic M; Ehrenfeld M; Lorber M; Bombardieri S; Shoenfeld Y
    Isr J Med Sci; 1996 Feb; 32(2):100-4. PubMed ID: 8631644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of thoracic outlet syndrome on the epidemiology and clinical presentation of apparently primary Raynaud's phenomenon. A prospective study in 570 patients.
    Pistorius MA; Planchon B
    Int Angiol; 1995 Mar; 14(1):60-4. PubMed ID: 7658106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome.
    Keenan EJ; Porter JM
    Surgery; 1983 Aug; 94(2):204-9. PubMed ID: 6308842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alopecia in systemic lupus erythematosus. Relation to disease manifestations.
    Wysenbeek AJ; Leibovici L; Amit M; Weinberger A
    J Rheumatol; 1991 Aug; 18(8):1185-6. PubMed ID: 1941821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hand angiography and Raynaud's syndrome.
    Rösch J; Porter JM
    Rofo; 1977 Jul; 127(1):30-7. PubMed ID: 142731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.